Rapport Therapeutics, Inc. (RAPP:NASDAQ) closed at $26.53 on October 22, 2026, up 5.87% on the day. The stock trades 49.9% below its 52-week high of $52.93 and 11.7% above its 52-week low of $23.75. Over the past year, it gained 0.6%. Rapport Therapeutics, Inc. is part of the Health Care sector.
In 252 trading sessions since October 22, 2025, RAPP closed higher on 132 days (52%). Its best day was March 31, 2026 (+13.00%) and its worst was September 23, 2026 (-17.70%). The stock moved 10% or more in a single session 3 times.
Rapport Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
Find more stocks like RAPP with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.